Screening for prostate cancer: A guidance statement from the clinical guidelines committee of the American college of physicians

Annals of Internal Medicine

Volumn 158, Issue 10, 2013, Pages 761-770

  Qaseem, Amir ^a   Barry, Michael J ^b   Denberg, Thomas D ^c   Owens, Douglas K ^d   Shekelle, Paul ^e  

^a not available   (United States)

^b not available   (United States)

^c not available   (United States)

^d not available   (United States)

^e not available   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; HIGH RISK PATIENT; HUMAN; LIFE EXPECTANCY; MALE; NON PROFIT ORGANIZATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; REVIEW; UNITED STATES; URINE INCONTINENCE; URINE RETENTION;

EID: 84878101564     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-158-10-201305210-00633     Document Type: Review

References (25)

1. National Cancer Institute. SEER Stat Fact Sheets: Prostate. Accessed at http://seer.cancer.gov/statfacts/html/prost.html on 20 March 2013.
2. Ries LA, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al, eds. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute. Accessed at http://seer.cancer.gov/csr/1975_2004 on 20 March 2013.
3. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101:374-383. [PMID: 19276453]
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249. [PMID: 19474385]
5. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute. Accessed at http://seer.cancer.gov/csr/1975_2008 on 20 March 2013.
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29. [PMID: 22237781]
7. Lim LS, Sherin K; ACPM Prevention Practice Committee. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice. Am J Prev Med. 2008;34:164-170. [PMID: 18201648]
8. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, et al; American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70-98. [PMID: 20200110]
9. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182: 2232-2241. [PMID: 19781717]
10. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:185-191. [PMID: 18678845]
11. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al; AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010;182:E839-42. [PMID: 20603348]
12. Qaseem A, Snow V, Owens DK, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. Ann Intern Med. 2010;153:194-199. [PMID: 20679562]
13. Federman DG, Goyal S, Kamina A, Peduzzi P, Concato J. Informed consent for PSA screening: does it happen? Eff Clin Pract. 1999;2:152-157. [PMID: 10539539]
14. Hoffman RM, Couper MP, Zikmund-Fisher BJ, Levin CA, McNaughton-Collins M, Helitzer DL, et al. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study). Arch Intern Med. 2009;169:1611-1618. [PMID: 19786681]
15. Lamplugh M, Gilmore P, Quinlan T, Cornford P. PSA testing: are patients aware of what lies ahead? Ann R Coll Surg Engl. 2006;88:284-288. [PMID: 16720000]
16. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319. [PMID: 19297565]
17. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328. [PMID: 19297566]
18. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012;366:981-990. [PMID: 22417251]
19. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al; PLCO Project Team. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125-132. [PMID: 22228146]
20. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al; Prostate Cancer Intervention Versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203-213. [PMID: 22808955]
21. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:762-771. [PMID: 21984740]
22. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28:1117-1123. [PMID: 20124165]
23. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101:1325-1329. [PMID: 19720969]
24. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013;158:145-153. [PMID: 23381039]
25. Merrill RM, Weed DL, Feuer EJ. The lifetime risk of developing prostate cancer in white and black men. Cancer Epidemiol Biomarkers Prev. 1997;6: 763-768. [PMID: 9332756]